Maple Rock Capital Partners’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$138M Buy
+466,238
New +$123M 2.86% 12

Other funds holding CRL

Maple Rock Capital Partners's CRL Position: Q3 2026 in Review

Maple Rock Capital Partners opened a new position in Charles River Laboratories (CRL) in Q3 2026: 466,238 shares worth $138M. The stake represents 2.86% of the portfolio and ranks #12 among its holdings.

642 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Maple Rock Capital Partners held 466,238 shares of Charles River Laboratories worth $138M as of Q3 2026.
  • Charles River Laboratories was a new Maple Rock Capital Partners position in Q3 2026.
  • Charles River Laboratories made up 2.86% of Maple Rock Capital Partners's portfolio in Q3 2026, its #12 holding.
  • 642 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Maple Rock Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.